EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
Despite The Controversy, Blockbuster Status Is Predicted
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.
